Bupropion

Generic Name: Bupropion

Brand Names: Aplenzin, Auvelity, Budeprion, Contrave, Forfivo, Wellbutrin, Zyban

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈ClNO

CAS Number: 34911-55-2

Unique Ingredient Identifier: 01ZG3TPX31

Background: Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the upta...

Indication: Bupropion is indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation.
...

Associated Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Major Depressive Disorder (MDD), Obesity, Seasonal Affective Disorder (SAD)

Associated Therapies: Smoking, Cessation, Weight Loss

Clinical Trials

Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia

Phase 4

Completed

Conditions: Obese
Cigarette-smoking
Schizophrenia

Interventions: Drug: Placebo Naltrexone
Drug: Naltrexone
Drug: Placebo Bupropion
Drug: Bupropion

First Posted Date: 2016-04-13

Last Posted Date: 2021-10-22

Lead Sponsor: Shanghai Mental Health Center

Target Recruit Count: 22

Registration Number: NCT02736474

Pharmacokinetic Study of Intranasal Esketamine and Its Effects on the Pharmacokinetics of Orally-Administered Midazolam and Bupropion in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Midazolam
Drug: Esketamine
Drug: Bupropion

First Posted Date: 2015-10-05

Last Posted Date: 2017-02-17

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 71

Registration Number: NCT02568176

Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia
Cigarette Smoking

Interventions: Drug: Nicotine replacement therapy
Drug: Bupropion
Behavioral: cognitive-behavioral smoking cessation counseling
Behavioral: Mobile Contingency Management
Behavioral: Stay Quit Coach
Behavioral: SMS text messaging

First Posted Date: 2015-04-17

Last Posted Date: 2019-07-10

Lead Sponsor: Duke University

Target Recruit Count: 35

Registration Number: NCT02420015

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

CYP2B6 Genetics and Drug Interactions in Healthy Volunteers

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: Efavirenz
Drug: Bupropion
Drug: Rosuvastatin
Drug: Montelukast

First Posted Date: 2015-03-27

Last Posted Date: 2017-10-11

Lead Sponsor: Indiana University

Target Recruit Count: 70

Registration Number: NCT02401256

Locations: 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States

Evaluation of the Potential Pharmacokinetic Interactions Between Probe Drugs in the Geneva Phenotyping Cocktail

Phase 1

Completed

Conditions: Drug Interaction

Interventions: Drug: Caffeine, omeprazole, flurbiprofen, dextromethorphan, midazolam
Drug: Fexofenadine
Drug: Bupropion

First Posted Date: 2015-03-18

Last Posted Date: 2017-02-07

Lead Sponsor: Jules Desmeules

Target Recruit Count: 30

Registration Number: NCT02391688

Locations: 🇨🇭
Centre de Recherche Clinique, HUG, Rue Gabrielle Perret-Gentil 4, Genève, Switzerland

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3

Terminated

Conditions: Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders

Interventions: Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium

First Posted Date: 2015-03-02

Last Posted Date: 2018-02-28

Lead Sponsor: Hannover Medical School

Target Recruit Count: 407

Registration Number: NCT02374567

Locations: 🇩🇪
Bezirkskrankenhaus Augsburg, Augsburg, Germany
🇩🇪
Krankenhaus Hedwigshöhe, Berlin, Germany
🇩🇪
Hannover Medical School, Hannover, Germany

and more 2 locations

Drug-Drug Interaction Study: ASP2151 and Bupropion

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Bupropion
Drug: ASP2151

First Posted Date: 2015-02-23

Last Posted Date: 2019-02-21

Lead Sponsor: Maruho Europe Limited

Target Recruit Count: 24

Registration Number: NCT02369172

Locations: 🇬🇧
Hammersmith Medicines Research Ltd, London, United Kingdom

Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers

Phase 4

Completed

Conditions: Tobacco Use Disorder
Homelessness

Interventions: Drug: Nicotine Patches
Behavioral: Smoking cessation counseling
Behavioral: mobile contingency management (mCM)
Drug: Nicotine rescue method
Drug: Bupropion

First Posted Date: 2014-09-19

Last Posted Date: 2022-01-04

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 133

Registration Number: NCT02245308

Locations: 🇺🇸
Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States

Bupropion for Depression in ESRD Patients on Hemodialysis

Phase 4

Terminated

Conditions: Major Depression
End Stage Renal Disease

Interventions: Drug: Fluoxetine
Drug: Bupropion

First Posted Date: 2014-09-12

Last Posted Date: 2018-07-17

Lead Sponsor: University of Arkansas

Target Recruit Count: 1

Registration Number: NCT02238977

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder

Phase 3

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Bupropion Matching Placebo
Drug: Bupropion
Drug: Escitalopram Matching Placebo
Drug: Escitalopram

First Posted Date: 2014-07-16

Last Posted Date: 2020-02-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 534

Registration Number: NCT02191397

Locations: 🇨🇳
GSK Investigational Site, Wuhan, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy